---
figid: PMC2993470__zmo0121062480001
figtitle: Collateral efficacy in GPCR signaling
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC2993470
filename: zmo0121062480001.jpg
figlink: /pmc/articles/PMC2993470/figure/F1/
number: F1
caption: Collateral efficacy in GPCR signaling. In the traditional paradigm of linear
  efficacy, a given agonist or antagonist for a GPCR initiates or inhibits a signaling
  pathway before the process is terminated by regulatory proteins such as GRKs and
  β-arrestins. In collateral or pluridimensional efficacy, a given ligand may be an
  antagonist for one pathway whereas simultaneously permitting activation of other
  pathways through G protein-dependent and -independent signaling. Therefore, multiple
  functions may be seen via a single receptor-ligand interaction and a subsequent
  unique receptor conformation change.
papertitle: Functional Selectivity in Adrenergic and Angiotensin Signaling Systems.
reftext: Chetan B. Patel, et al. Mol Pharmacol. 2010 Dec;78(6):983-992.
year: '2010'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8698452
figid_alias: PMC2993470__F1
figtype: Figure
redirect_from: /figures/PMC2993470__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2993470__zmo0121062480001.html
  '@type': Dataset
  description: Collateral efficacy in GPCR signaling. In the traditional paradigm
    of linear efficacy, a given agonist or antagonist for a GPCR initiates or inhibits
    a signaling pathway before the process is terminated by regulatory proteins such
    as GRKs and β-arrestins. In collateral or pluridimensional efficacy, a given ligand
    may be an antagonist for one pathway whereas simultaneously permitting activation
    of other pathways through G protein-dependent and -independent signaling. Therefore,
    multiple functions may be seen via a single receptor-ligand interaction and a
    subsequent unique receptor conformation change.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Oamb
  - Arr2
  - grk
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - GNAS
  - GNAL
  - GNAQ
  - GNA11
  - GNA14
  - GNA15
  - GNA12
  - GNA13
  - GRK1
  - GRK4
  - GRK5
  - GRK6
  - GRK7
  - GRK2
  - GRK3
---
